Jeffrey Glantz Blue, MD
Family Practice · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 29
- 7 carriers
- Offices
- 2
Offices
2 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: 059796 · El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
29 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Blue’s office at (408) 358-2663 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
29 of 29 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$77,960
Medicare paid this office $77,960 for 218 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 151 | $43,431 | $109 |
| Short return visit (20+ min) | 100 | $12,292 | $76 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 48 | $7,559 | $157 |
| Long return visit (40+ min) | 26 | $4,481 | $140 |
| New patient visit (45+ min) | 22 | $3,301 | $150 |
See all 9 services
| Return visit (30+ min) | 151 | $43,431 | $109 |
| Short return visit (20+ min) | 100 | $12,292 | $76 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 48 | $7,559 | $157 |
| Long return visit (40+ min) | 26 | $4,481 | $140 |
| New patient visit (45+ min) | 22 | $3,301 | $150 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 13 | $2,588 | $199 |
| New patient visit (30+ min) | 18 | $1,178 | $65 |
| Injection of drug or substance under skin or into muscle | 14 | $572 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 21 | $324 | $14 |
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
218 Original Medicare patients in 2024. Average age 73 · Women 34% · Health risk score 0.78. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 61% · Coronary heart disease 27% · Diabetes 17% · Chronic kidney disease 14% · Cancer 12% · Atrial fibrillation 12% · COPD 7% · Stroke 7% · Depression 6% · Dementia 5%.
The office billed $330,324, Medicare allowed $107,610 and paid $77,960; for 4,428 services of 29 kinds; $79 of it was for drugs given in the office and $77,881 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 218 | 4,428 | 73 | 0.78 | $330,324 | $77,960 |
| 2023 | 173 | 2,350 | 74 | 0.79 | $250,974 | $57,855 |
| 2022 | 209 | 1,075 | 73 | 0.76 | $291,873 | $74,587 |
| 2021 | 152 | 1,869 | 72 | 0.80 | $154,178 | $55,253 |
| 2020 | 134 | 1,394 | 72 | 0.90 | $106,065 | $57,365 |
| 2019 | 142 | 1,916 | 72 | 0.90 | $129,441 | $68,420 |
| 2018 | 112 | 2,148 | 72 | 0.87 | $127,079 | $65,801 |
| 2017 | 125 | 1,919 | 71 | 0.85 | $118,905 | $58,554 |
| 2016 | 136 | 2,489 | 71 | 0.78 | $146,425 | $74,627 |
| 2015 | 119 | 1,774 | 69 | 0.86 | $107,038 | $55,483 |
| 2014 | 90 | 1,381 | 69 | 0.78 | $87,553 | $44,385 |
| 2013 | 77 | 846 | 68 | 0.92 | $56,261 | $27,788 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 129 | $29,976 | $101 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 50 | $7,800 | $156 |
| Long return visit (40+ min) | 26 | $4,906 | $153 |
| Short return visit (20+ min) | 45 | $4,619 | $66 |
| New patient visit (30+ min) | 11 | $775 | $70 |
| Injection of drug or substance under skin or into muscle | 17 | $729 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 12 | $170 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $11 | None |
2022: 13 services
| Return visit (30+ min) | 139 | $34,815 | $110 |
| Short return visit (20+ min) | 83 | $10,150 | $70 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 41 | $6,505 | $159 |
| Long return visit (40+ min) | 16 | $3,960 | $165 |
| New patient visit (45+ min) | 11 | $1,743 | $158 |
| New patient visit (30+ min) | 17 | $1,724 | $101 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 21 | $1,475 | $70 |
| X-ray of knee, 4 or more views | 16 | $928 | $49 |
| Injection of drug or substance under skin or into muscle | 18 | $926 | $14 |
| Administration of influenza virus vaccine | 21 | $782 | $37 |
| X-ray of shoulder, minimum of 2 views | 12 | $555 | $37 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 38 | $533 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $11 | None |
2021: 11 services
| Return visit (30+ min) | 82 | $22,301 | $102 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 36 | $5,739 | $159 |
| Short return visit (20+ min) | 55 | $5,144 | $64 |
| Long return visit (40+ min) | 24 | $3,924 | $151 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $2,301 | $89 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 26 | $1,794 | $66 |
| New patient visit (30+ min) | 11 | $866 | $79 |
| Administration of influenza virus vaccine | 26 | $583 | $22 |
| Injection of drug or substance under skin or into muscle | 12 | $517 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | $335 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $8 | None |
2020: 11 services
| Return visit (30+ min) | 73 | $16,853 | $85 |
| Therapy procedure using functional activities | 30 | $9,375 | $31 |
| Therapy procedure using manual technique, each 15 minutes | 34 | $6,054 | $19 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 34 | $4,653 | $137 |
| Short return visit (20+ min) | 47 | $4,128 | $60 |
| Pneumococcal vaccine, 13-valent | 14 | $2,952 | $211 |
| Influenza vaccine split virus, preservative free | 44 | $2,738 | $61 |
| Long return visit (40+ min) | 12 | $1,947 | $122 |
| Evaluation for physical therapy, typically 30 minutes | 27 | $1,851 | $62 |
| Administration of influenza virus vaccine | 44 | $816 | $18 |
| Administration of pneumococcal vaccine | 20 | $343 | $17 |
2019: 12 services
| Return visit (30+ min) | 75 | $15,542 | $84 |
| Therapy procedure using functional activities | 33 | $14,689 | $33 |
| Therapy procedure using manual technique, each 15 minutes | 35 | $11,893 | $20 |
| Short return visit (20+ min) | 57 | $6,432 | $56 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 31 | $4,109 | $133 |
| Evaluation for physical therapy, typically 30 minutes | 32 | $2,803 | $76 |
| Influenza vaccine split virus, preservative free | 34 | $1,856 | $55 |
| Long return visit (40+ min) | 11 | $1,562 | $120 |
| New patient visit (45+ min) | 12 | $1,308 | $109 |
| Administration of influenza virus vaccine | 38 | $678 | $17 |
| Injection of drug or substance under skin or into muscle | 11 | $297 | $13 |
| Administration of pneumococcal vaccine | 15 | $261 | $17 |
2018: 11 services
| Therapy procedure using functional activities | 40 | $16,362 | $33 |
| Therapy procedure using manual technique, each 15 minutes | 47 | $13,893 | $18 |
| Return visit (30+ min) | 60 | $10,646 | $84 |
| Short return visit (20+ min) | 57 | $6,140 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $3,867 | $133 |
| Evaluation for physical therapy, typically 30 minutes | 34 | $2,594 | $70 |
| Influenza vaccine split virus, preservative free | 33 | $1,723 | $49 |
| Administration of influenza virus vaccine | 32 | $732 | $22 |
| Injection of drug or substance under skin or into muscle | 15 | $391 | $16 |
| Administration of pneumococcal vaccine | 14 | $323 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 19 | $18 | None |
2017: 15 services
| Therapy procedure using manual technique, each 15 minutes | 47 | $13,342 | $19 |
| Return visit (30+ min) | 61 | $10,894 | $82 |
| Therapy procedure using functional activities | 41 | $10,094 | $28 |
| Short return visit (20+ min) | 48 | $4,057 | $52 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 26 | $3,422 | $132 |
| Pneumococcal vaccine, 13-valent | 18 | $3,153 | $175 |
| Evaluation for physical therapy, typically 30 minutes | 28 | $2,146 | $67 |
| New patient visit (45+ min) | 13 | $1,303 | $100 |
| Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 14 | $890 | $9 |
| Influenza vaccine split virus, preservative free | 18 | $741 | $41 |
| Administration of pneumococcal vaccine | 20 | $560 | $28 |
| Administration of influenza virus vaccine | 19 | $517 | $27 |
| Injection of drug or substance under skin or into muscle | 14 | $515 | $20 |
| Automated urinalysis test | 12 | $48 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $13 | None |
2016: 15 services
| Therapy procedure using manual technique, each 15 minutes | 55 | $18,303 | $20 |
| Therapy procedure using functional activities | 49 | $16,190 | $29 |
| Return visit (30+ min) | 67 | $12,121 | $78 |
| Short return visit (20+ min) | 56 | $6,336 | $56 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 33 | $4,315 | $131 |
| Physical therapy evaluation | 37 | $2,530 | $63 |
| Pneumococcal vaccine, 13-valent | 11 | $1,952 | $177 |
| New patient visit (45+ min) | 13 | $1,617 | $124 |
| Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 21 | $1,571 | $9 |
| New patient visit (30+ min) | 12 | $957 | $80 |
| Influenza vaccine split virus, preservative free | 17 | $672 | $40 |
| Administration of pneumococcal vaccine | 20 | $591 | $30 |
| Administration of influenza virus vaccine | 19 | $565 | $30 |
| Injection of drug or substance under skin or into muscle | 13 | $519 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $18 | None |
2015: 11 services
| Therapy procedure using manual technique, each 15 minutes | 39 | $13,390 | $21 |
| Therapy procedure using functional activities | 36 | $12,041 | $27 |
| Return visit (30+ min) | 54 | $11,801 | $86 |
| Short return visit (20+ min) | 43 | $4,361 | $57 |
| Physical therapy evaluation | 30 | $2,264 | $67 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,712 | $132 |
| Long return visit (40+ min) | 11 | $1,337 | $122 |
| Influenza vaccine split virus, preservative free | 15 | $534 | $36 |
| Administration of influenza virus vaccine | 16 | $426 | $27 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | $192 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $15 | None |
2014: 9 services
| Return visit (30+ min) | 46 | $10,240 | $80 |
| Therapy procedure using functional activities | 29 | $9,481 | $27 |
| Therapy procedure using manual technique, each 15 minutes | 31 | $8,134 | $21 |
| Short return visit (20+ min) | 40 | $3,581 | $52 |
| Physical therapy evaluation | 35 | $2,392 | $61 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 11 | $2,072 | $188 |
| Long return visit (40+ min) | 15 | $1,989 | $124 |
| Influenza vaccine split virus, preservative free | 19 | $651 | $33 |
| Administration of influenza virus vaccine | 19 | $523 | $26 |
2013: 8 services
| Return visit (30+ min) | 46 | $8,980 | $79 |
| Therapy procedure using functional activities | 23 | $5,379 | $27 |
| Short return visit (20+ min) | 35 | $3,045 | $52 |
| Therapy procedure using manual technique, each 15 minutes | 20 | $2,988 | $23 |
| Long return visit (40+ min) | 12 | $1,545 | $103 |
| Physical therapy evaluation | 21 | $1,320 | $63 |
| Injection of drug or substance under skin or into muscle | 11 | $603 | $23 |
| Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 13 | $572 | $10 |
Drugs they prescribed that Part D paid
$136,655
Pharmacies billed $136,655 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (69 of 1,532) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
1,384 generic and fewer than 11 brand-name prescriptions · $136,655 in drug cost · 37 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 20 | $23,263 | $1,163 |
| Eliquis | 11 | $6,281 | $571 |
| Vascepa | 11 | $4,441 | $404 |
| Rosuvastatin | 121 | $2,187 | $18 |
| Gabapentin | 26 | $1,765 | $68 |
See all 37 drugs
| Ozempic | 20 | $23,263 | $1,163 |
| Eliquis | 11 | $6,281 | $571 |
| Vascepa | 11 | $4,441 | $404 |
| Rosuvastatin | 121 | $2,187 | $18 |
| Gabapentin | 26 | $1,765 | $68 |
| Ezetimibe | 21 | $1,657 | $79 |
| Hydrocodone-Acetaminophen | 38 | $1,447 | $38 |
| Amlodipine-Olmesartan | 15 | $905 | $60 |
| Atorvastatin | 68 | $730 | $11 |
| Olmesartan Medoxomil | 46 | $685 | $15 |
| Levothyroxine | 64 | $683 | $11 |
| Metoprolol | 35 | $577 | $16 |
| Losartan | 50 | $563 | $11 |
| Clonazepam | 49 | $469 | $10 |
| Tamsulosin | 27 | $456 | $17 |
| Amlodipine Besylate | 46 | $451 | $10 |
| Pantoprazole | 38 | $440 | $12 |
| Celecoxib | 16 | $387 | $24 |
| Finasteride | 30 | $341 | $11 |
| Pravastatin | 13 | $325 | $25 |
| Testosterone Cypionate | 13 | $324 | $25 |
| Allopurinol | 21 | $300 | $14 |
| Potassium Chloride | 11 | $256 | $23 |
| Pregabalin | 20 | $221 | $11 |
| Lorazepam | 27 | $219 | $8 |
| Baclofen | 12 | $192 | $16 |
| Metformin | 19 | $159 | $8 |
| Sertraline | 19 | $129 | $7 |
| Metformin Hcl Er | 25 | $108 | $4 |
| Lisinopril | 32 | $108 | $3 |
| Trazodone | 23 | $88 | $4 |
| Triamcinolone Acetonide | 14 | $84 | $6 |
| Hydrochlorothiazide | 18 | $80 | $4 |
| Omeprazole | 18 | $66 | $4 |
| Tramadol | 14 | $44 | $3 |
| Meloxicam | 18 | $38 | $2 |
| Cyclobenzaprine | 12 | $38 | $3 |
Year by year
| 2024 | 1,532 | 169 | 5% (69) | None | $136,655 |
| 2023 | 1,479 | 141 | 6% (82) | None | $185,779 |
| 2022 | 1,030 | 115 | 7% (67) | None | $138,433 |
| 2021 | 775 | 84 | 7% (55) | None | $133,200 |
| 2020 | 754 | 80 | 7% (49) | 12% | $126,012 |
| 2019 | 626 | 83 | 9% (59) | 10% | $61,066 |
| 2018 | 491 | 73 | None | 18% | $68,307 |
| 2017 | 322 | 64 | None | 15% | $26,285 |
| 2016 | 321 | 53 | 4% (12) | 10% | $9,791 |
| 2015 | 427 | 54 | 3% (11) | None | $16,722 |
| 2014 | 401 | 47 | 6% (23) | None | $19,030 |
| 2013 | 507 | 49 | 13% (64) | None | $27,935 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Rosuvastatin | 133 | $4,610 | $35 |
| Gabapentin | 62 | $1,886 | $30 |
| Ezetimibe | 16 | $1,507 | $94 |
| Olmesartan Medoxomil | 51 | $1,403 | $28 |
| Celecoxib | 17 | $1,120 | $66 |
| Amlodipine-Olmesartan | 13 | $1,060 | $82 |
| Atorvastatin | 71 | $921 | $13 |
| Metoprolol | 47 | $903 | $19 |
| Levothyroxine | 47 | $835 | $18 |
| Hydrocodone-Acetaminophen | 48 | $814 | $17 |
| Trazodone | 41 | $636 | $16 |
| Pantoprazole | 45 | $595 | $13 |
| Pregabalin | 21 | $580 | $28 |
| Metformin Hcl Er | 40 | $571 | $14 |
| Losartan | 49 | $552 | $11 |
| Clonazepam | 33 | $427 | $13 |
| Finasteride | 28 | $421 | $15 |
| Amlodipine Besylate | 49 | $384 | $8 |
| Tamsulosin | 28 | $326 | $12 |
| Alendronate | 12 | $246 | $21 |
| Lisinopril | 28 | $183 | $7 |
| Omeprazole | 24 | $157 | $7 |
| Buspirone | 17 | $155 | $9 |
| Azithromycin | 20 | $146 | $7 |
| Montelukast | 11 | $145 | $13 |
| Cyclobenzaprine | 16 | $122 | $8 |
| Metformin | 14 | $120 | $9 |
| Sertraline | 11 | $110 | $10 |
| Lorazepam | 21 | $97 | $5 |
| Baclofen | 11 | $66 | $6 |
| Hydrochlorothiazide | 11 | $43 | $4 |
| Meloxicam | 14 | $24 | $2 |
2022: 32 drugs
| Copaxone | 12 | $91,344 | $7,612 |
| Vascepa | 13 | $6,457 | $497 |
| Celecoxib | 29 | $1,090 | $38 |
| Ezetimibe | 13 | $1,081 | $83 |
| Rosuvastatin | 48 | $1,070 | $22 |
| Gabapentin | 58 | $989 | $17 |
| Levothyroxine | 46 | $949 | $21 |
| Dextroamphetamine-Amphetamine | 15 | $818 | $55 |
| Hydrocodone-Acetaminophen | 31 | $756 | $24 |
| Olmesartan Medoxomil | 23 | $648 | $28 |
| Hydromorphone | 12 | $594 | $49 |
| Pregabalin | 24 | $580 | $24 |
| Valsartan | 11 | $557 | $51 |
| Metoprolol | 30 | $544 | $18 |
| Atorvastatin | 40 | $475 | $12 |
| Tamsulosin | 24 | $400 | $17 |
| Pravastatin | 20 | $289 | $14 |
| Bupropion Xl | 13 | $255 | $20 |
| Pantoprazole | 16 | $246 | $15 |
| Amlodipine Besylate | 47 | $239 | $5 |
| Metformin Hcl Er | 22 | $233 | $11 |
| Baclofen | 11 | $218 | $20 |
| Losartan | 30 | $207 | $7 |
| Finasteride | 17 | $198 | $12 |
| Omeprazole | 15 | $161 | $11 |
| Lisinopril | 17 | $142 | $8 |
| Montelukast | 20 | $139 | $7 |
| Losartan-Hydrochlorothiazide | 11 | $97 | $9 |
| Alendronate | 15 | $86 | $6 |
| Triamcinolone Acetonide | 12 | $78 | $6 |
| Clonazepam | 16 | $52 | $3 |
| Hydrochlorothiazide | 11 | $47 | $4 |
2021: 23 drugs
| Copaxone | 12 | $89,636 | $7,470 |
| Xarelto | 16 | $7,869 | $492 |
| Rosuvastatin | 47 | $1,731 | $37 |
| Levothyroxine | 43 | $900 | $21 |
| Celecoxib | 21 | $731 | $35 |
| Hydromorphone | 15 | $663 | $44 |
| Metoprolol | 24 | $572 | $24 |
| Atorvastatin | 31 | $516 | $17 |
| Hydrocodone-Acetaminophen | 26 | $502 | $19 |
| Amlodipine Besylate | 40 | $493 | $12 |
| Tamsulosin | 19 | $492 | $26 |
| Pravastatin | 19 | $381 | $20 |
| Lisinopril | 37 | $359 | $10 |
| Omeprazole | 16 | $341 | $21 |
| Metformin Hcl Er | 15 | $280 | $19 |
| Pantoprazole | 20 | $249 | $12 |
| Losartan | 20 | $234 | $12 |
| Baclofen | 15 | $232 | $15 |
| Gabapentin | 16 | $158 | $10 |
| Bupropion Xl | 11 | $147 | $13 |
| Clonazepam | 24 | $115 | $5 |
| Metformin | 12 | $86 | $7 |
| Hydrochlorothiazide | 11 | $41 | $4 |
2020: 21 drugs
| Copaxone | 12 | $89,636 | $7,470 |
| Rosuvastatin | 52 | $1,860 | $36 |
| Levothyroxine | 53 | $1,319 | $25 |
| Celecoxib | 25 | $1,071 | $43 |
| Metoprolol | 21 | $746 | $36 |
| Hydromorphone | 23 | $676 | $29 |
| Metformin Hcl Er | 20 | $660 | $33 |
| Morphine Sulfate Er | 11 | $586 | $53 |
| Amlodipine Besylate | 42 | $502 | $12 |
| Losartan | 32 | $484 | $15 |
| Lisinopril | 34 | $390 | $11 |
| Atorvastatin | 30 | $371 | $12 |
| Tamsulosin | 11 | $360 | $33 |
| Bupropion Xl | 11 | $278 | $25 |
| Omeprazole | 19 | $201 | $11 |
| Montelukast | 12 | $191 | $16 |
| Hydrochlorothiazide | 19 | $169 | $9 |
| Clonazepam | 29 | $162 | $6 |
| Metformin | 16 | $157 | $10 |
| Ondansetron Odt | 13 | $144 | $11 |
| Lorazepam | 12 | $123 | $10 |
2019: 15 drugs
| Pazeo | 19 | $4,707 | $248 |
| Rosuvastatin | 51 | $2,476 | $49 |
| Metformin Hcl Er | 17 | $749 | $44 |
| Oxycodone-Acetaminophen | 25 | $638 | $26 |
| Levothyroxine | 35 | $570 | $16 |
| Losartan | 29 | $357 | $12 |
| Atorvastatin | 35 | $324 | $9 |
| Amlodipine Besylate | 24 | $313 | $13 |
| Montelukast | 23 | $253 | $11 |
| Lisinopril | 22 | $238 | $11 |
| Clonazepam | 22 | $174 | $8 |
| Omeprazole | 12 | $172 | $14 |
| Metformin | 14 | $95 | $7 |
| Latanoprost | 15 | $75 | $5 |
| Hydrochlorothiazide | 17 | $41 | $2 |
2018: 13 drugs
| Pazeo | 22 | $3,987 | $181 |
| Rosuvastatin | 24 | $729 | $30 |
| Olopatadine | 14 | $627 | $45 |
| Levothyroxine | 21 | $410 | $20 |
| Losartan | 40 | $366 | $9 |
| Metformin Hcl Er | 13 | $342 | $26 |
| Atorvastatin | 32 | $322 | $10 |
| Latanoprost | 25 | $306 | $12 |
| Valsartan | 11 | $239 | $22 |
| Amlodipine Besylate | 29 | $234 | $8 |
| Lisinopril | 15 | $176 | $12 |
| Metformin | 15 | $151 | $10 |
| Clonazepam | 14 | $110 | $8 |
2017: 9 drugs
| Metformin Hcl Er | 14 | $3,532 | $252 |
| Levothyroxine | 11 | $414 | $38 |
| Valsartan | 11 | $400 | $36 |
| Latanoprost | 24 | $360 | $15 |
| Atorvastatin | 28 | $326 | $12 |
| Amlodipine Besylate | 12 | $95 | $8 |
| Lisinopril | 12 | $88 | $7 |
| Atenolol | 11 | $70 | $6 |
| Metoprolol | 11 | $45 | $4 |
2016: 8 drugs
| Levothyroxine | 16 | $443 | $28 |
| Atorvastatin | 46 | $404 | $9 |
| Latanoprost | 17 | $187 | $11 |
| Lisinopril | 21 | $161 | $8 |
| Metformin | 15 | $111 | $7 |
| Losartan-Hydrochlorothiazide | 13 | $82 | $6 |
| Metformin Hcl Er | 11 | $53 | $5 |
| Metoprolol | 14 | $53 | $4 |
2015: 14 drugs
| Valsartan | 21 | $865 | $41 |
| Levothyroxine | 18 | $575 | $32 |
| Atorvastatin | 34 | $405 | $12 |
| Doxepin | 11 | $390 | $35 |
| Zolpidem | 17 | $259 | $15 |
| Amlodipine Besylate | 27 | $177 | $7 |
| Metoprolol | 22 | $142 | $6 |
| Latanoprost | 20 | $138 | $7 |
| Metformin | 13 | $109 | $8 |
| Clonazepam | 11 | $108 | $10 |
| Losartan | 11 | $89 | $8 |
| Losartan-Hydrochlorothiazide | 12 | $76 | $6 |
| Alprazolam | 13 | $68 | $5 |
| Tramadol | 11 | $58 | $5 |
2014: 11 drugs
| Diovan | 16 | $3,285 | $205 |
| Atorvastatin | 32 | $507 | $16 |
| Lisinopril-Hydrochlorothiazide | 13 | $218 | $17 |
| Levothyroxine | 24 | $218 | $9 |
| Hydrocodone-Acetaminophen | 13 | $208 | $16 |
| Metformin | 16 | $160 | $10 |
| Losartan | 21 | $155 | $7 |
| Amlodipine Besylate | 24 | $154 | $6 |
| Latanoprost | 16 | $138 | $9 |
| Alprazolam | 13 | $113 | $9 |
| Hydrochlorothiazide | 13 | $47 | $4 |
2013: 15 drugs
| Novolog | 11 | $4,516 | $411 |
| Diovan | 13 | $3,200 | $246 |
| Atorvastatin | 19 | $712 | $37 |
| Hydrocodone-Acetaminophen | 24 | $525 | $22 |
| Tramadol | 20 | $340 | $17 |
| Oxycodone | 11 | $325 | $30 |
| Lisinopril-Hydrochlorothiazide | 26 | $314 | $12 |
| Levothyroxine | 24 | $239 | $10 |
| Losartan | 26 | $231 | $9 |
| Alprazolam | 16 | $219 | $14 |
| Donepezil | 14 | $215 | $15 |
| Latanoprost | 14 | $202 | $14 |
| Meloxicam | 13 | $109 | $8 |
| Diazepam | 21 | $95 | $5 |
| Zolpidem | 12 | $59 | $5 |
Money from drug and device companies
$798 in 2025
| 2025 | 13 | 40 | None | $798 |
| 2024 | 7 | 34 | None | $604 |
| 2023 | 2 | 11 | None | $228 |
| 2022 | 1 | 3 | None | $46 |
| 2021 | 2 | 2 | None | $146 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Antares Pharma | Xyosted | $177 | 15 payments
|
| Heartflow | Ffrct | $144 | 2 payments
|
| Abbvie | Ubrelvy | $139 | 7 payments
|
| Lilly USA | Mounjaro | $88 | 4 payments
|
| Amgen | Repatha | $47 | 2 payments
|
| Verity Pharmaceuticals | Tlando | $41 | 2 payments
|
See all 40 published payments
| Amgen | Meals · 2025-12-17 | Repatha | $28 |
| Abbvie | Meals · 2025-12-03 | Qulipta | $6 |
| Antares Pharma | Meals · 2025-12-03 | Xyosted | $21 |
| Abbvie | Meals · 2025-11-06 | Ubrelvy | $21 |
| Pfizer | Meals · 2025-10-29 | Paxlovid | $20 |
| Antares Pharma | Meals · 2025-10-22 | Xyosted | $17 |
| Abbvie | Meals · 2025-10-16 | Ubrelvy | $28 |
| Novo Nordisk | Meals · 2025-10-09 | Wegovy | $24 |
| Heartflow | Meals · 2025-09-16 | Ffrct | $102 |
| Heartflow | Meals · 2025-09-16 | Ffrct | $42 |
| Tolmar | Meals · 2025-09-16 | Jatenzo | $16 |
| Lilly USA | Meals · 2025-09-15 | Mounjaro | $21 |
| Antares Pharma | Meals · 2025-09-10 | Xyosted | $18 |
| Verity Pharmaceuticals | Meals · 2025-09-02 | Tlando | $19 |
| Amgen | Meals · 2025-08-25 | Otezla | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-21 | Caplyta | $26 |
| Lilly USA | Meals · 2025-07-18 | Mounjaro | $27 |
| Antares Pharma | Meals · 2025-07-15 | Xyosted | $16 |
| Antares Pharma | Meals · 2025-07-15 | Xyosted | $3 |
| Antares Pharma | Meals · 2025-06-19 | Xyosted | $4 |
| Antares Pharma | Meals · 2025-06-18 | Xyosted | $17 |
| Antares Pharma | Meals · 2025-05-22 | Xyosted | $3 |
| Antares Pharma | Meals · 2025-05-21 | Xyosted | $15 |
| Lilly USA | Meals · 2025-05-16 | Mounjaro | $21 |
| Exact Sciences | Meals · 2025-04-24 | Cologuard Collection Kit | $23 |
| Antares Pharma | Meals · 2025-04-23 | Xyosted | $7 |
| Abbvie | Meals · 2025-03-14 | Ubrelvy | $34 |
| Verity Pharmaceuticals | Meals · 2025-03-14 | Tlando | $22 |
| Antares Pharma | Meals · 2025-03-13 | Xyosted | $17 |
| Antares Pharma | Meals · 2025-03-12 | Xyosted | $6 |
| Abbvie | Meals · 2025-03-06 | Qulipta | $9 |
| Novartis Pharmaceuticals | Meals · 2025-02-24 | Leqvio | $21 |
| Pfizer | Meals · 2025-02-20 | Paxlovid | $15 |
| Abbott Laboratories | Meals · 2025-02-10 | Freestyle Libre 3 | $17 |
| Antares Pharma | Meals · 2025-02-05 | Xyosted | $14 |
| Antares Pharma | Meals · 2025-02-05 | Xyosted | $5 |
| Abbvie | Meals · 2025-02-01 | Ubrelvy | $17 |
| Lilly USA | Meals · 2025-01-22 | Mounjaro | $19 |
| Abbvie | Meals · 2025-01-11 | Ubrelvy | $25 |
| Antares Pharma | Meals · 2025-01-08 | Xyosted | $15 |
See earlier years (2024, 2023, 2022, 2021)
2024: $604
| Abbvie | Qulipta | $196 | 10 payments
|
| Antares Pharma | Xyosted | $173 | 15 payments
|
| Medtronic | Venaseal | $82 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $64 | 3 payments
|
| Verity Pharmaceuticals | Tlando | $47 | 3 payments
|
| Novo Nordisk | Wegovy | $24 | 1 payment
|
| Ossur Americas | Miami J | $17 | 1 payment
|
2023: $228
| AbbVie | Qulipta | $206 | 10 payments
|
| Pfizer | Paxlovid | $23 | 1 payment
|
2022: $46
| Abbvie | Ubrelvy | $46 | 3 payments
|
2021: $146
| NuVasive | Xlif | $125 | 1 payment
|
| AbbVie | Vraylar | $21 | 1 payment
|
Professional record
- NPI
- 1801900220
- Licence
- CA A060369
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207QS0010X (207QS0010X)
- Mailing address
- 221 E Hacienda Ave Ste C, Campbell, CA, 95008
- NPI first listed
- 2006-08-19
- NPI last updated
- 2024-11-12
- NPI record certified
- 2024-11-12
This is when the NPI record was last certified, not a medical board exam.